Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease

Neuropharmacology

Volumn 72, Issue , 2013, Pages 291-300

  Kosaraju, Jayasankar ^a   Gali, Chaitanya Chakravarthi ^a   Khatwal, Rizwan Basha ^a   Dubala, Anil ^a   Chinni, Santhivardhan ^a   Holsinger, R M Damian ^b   Madhunapantula, V Subba Rao ^c   Nataraj, Satish Kumar Muthureddy ^a   Basavan, Duraiswamy ^a  

^a JSS COLLEGE OF PHARMACY   (India)

^b UNIVERSITY OF SYDNEY   (Australia)

^c JSS MEDICAL COLLEGE   (India)

Author keywords

Amyloid beta; Glucagon like peptide 1; Hippocampus; Inflammatory markers; Tau; Type 2 diabetes; Wistar rats

Indexed keywords

AMYLOID BETA PROTEIN; GLUCAGON LIKE PEPTIDE 1; SAXAGLIPTIN; STREPTOZOCIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; HIPPOCAMPUS; MALE; MEMORY CONSOLIDATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TREATMENT DURATION;

EID: 84884829726     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.04.008     Document Type: Article

References (54)

1. Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I., Iqbal, K., 2001. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/ straight fila-ments. Proc. Natl. Acad. Sci. U. S. A. 98, 6923-6928. (Pubitemid 32538318)
2. Alzheimer's Association, 2012. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131-168.
3. Apelt, J., Schliebs, R., 2001. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged and transgenic transgenicTg2576 mice with Alzheimer plaque pathology. Brain Res. 894, 21-30. (Pubitemid 32197594)
4. Chen, S., Liu, A.R., An, F.M., Yao, W.B., Gao, X.D., 2012. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) 34, 1211-1224.
5. D'Amico, M., Di Filippo, C., Marfella, R., Abbatecola, A.M., Ferraraccio, F., Rossi, F., Paolisso, G., 2010. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp. Gerontol. 45, 202-207.
6. Dickson, D.W., 1997. The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56, 321-339. (Pubitemid 27465015)
7. During, M.J., Cao, L., Zuzga, D.S., Francis, J.S., Fitzsimons, H.L., Jiao, X., Bland, R.J., Klugmann, M., Banks,W.A., Drucker, D.J., Haile, C.N., 2003. Glucagon-like peptide- 1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 1173-1179. (Pubitemid 37173702)
8. El-Agnaf, O.M., Mahil, D.S., Patel, B.P., Austen, B.M., 2000. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem. Biophys. Res. Commun. 273, 1003-1007. (Pubitemid 30481069)
9. Findeis, M.A., 2007. The role of amyloid b peptide 42 in Alzheimer's disease. Pharmacol. Ther. 116, 266-286. (Pubitemid 47451506)
10. Fodero-Tavoletti, M.T., Villemagne, V.L., Rowe, C.C., Masters, C.L., Barnham, K.J., Cappai, R., 2011. Amyloid-b: the seeds of darkness. Int. J. Biochem. Cell. Biol. 43, 1247-1251.
11. Froelich, L., Ding, A., Hoyers, S., 1995. Holeboard maze-learning deficits and brain monoaminergic neurotransmitter concentrations in rats after intracerebroventricular injection of 3-Bromopyruvate. Pharmacol. Biochem. Behav. 51, 917-922.
12. Gengler, S., McClean, P.L., McCurtin, R., Gault, V.A., Holscher, C., 2010. Val(8) GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33, 265-276.
13. Glenner, G.G., Wong, C.W., 1984. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890. (Pubitemid 14104991)
14. Goedert, M., Spillantini, M.G., Cairns, N.J., Crowther, R.A., 1992. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8, 159-168.
15. Green, B.D., Peter, R.F., Clifford, J.B., 2006. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab. Vasc. Dis. Res. 3, 159-165. (Pubitemid 44902481)
16. Grunblatt, E., Salkovic-Petrisic, M., Osmanovic, J., Riederer, P., Hoyer, S., 2007. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J. Neurochem. 101, 757-770. (Pubitemid 46633313)
17. Grutzendler, J., Morris, J.C., 2001. Cholinesterase inhibitors for Alzheimer's disease. Drugs 61, 41-52. (Pubitemid 32109312)
18. Hamaguchi, T., Ono, K., Yamada, M., 2006. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell. Mol. Life Sci. 63, 1538-1552. (Pubitemid 44156750)
19. Hamilton, A., Holscher, C., 2009. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 20, 1161-1166.
20. Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
21. Holscher, C., 2010. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat. CNS Drug Discov. 5, 109-117.
22. Ishrat, T., Parveen, K., Khan, M.M., Khuwaja, G., Khan, M.B., Yousuf, S., Ahmad, A., Shrivastav, P., Islam, F., 2009. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res. 1281, 117-127.
23. Jarrett, J.T., Berger, E.P., Lansbury Jr., P.T., 1993. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697. (Pubitemid 23162022)
24. Kania, D.S., Gonzalvo, J.D., Weber, Z.A., 2011. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus. Clin. Ther. 33, 1005-1022.
25. Kastin, A.J., Akerstrom, V., Pan, W., 2002. Interactions of glucagon-like peptide-1 (GLP-1) with the bloodebrain barrier. J. Mol. Neurosci. 18, 7-14. (Pubitemid 34252619)
26. Kavirajan, H., Schneider, L.S., 2007. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 6, 782-792. (Pubitemid 47243710)
27. Kikkawa, F., Kajiyama, H., Shibata, K., Ino, K., Nomura, S., Mizutani, S., 2005. Dipeptidyl peptidase IV in tumor progression. Biochim. Biophys. Acta 1751, 45-51. (Pubitemid 41033293)
28. Koistinaho, J., Malm, T., Goldsteins, G., 2011. Glycogen synthase kinase-3b: a mediator of inflammation in Alzheimer's disease? Int. J. Alzheimers Dis., 129753 http://dx.doi.org/10.4061/2011/129753.
29. Kosik, K.S., Orecchio, L.D., Bakalis, S., Neve, R.L., 1989. Developmentally regulated ex-pression of specific tau sequences. Neuron 4, 1389-1397.
30. Li, L., Zhang, Z.F., Holscher, C., Gao, C., Jiang, Y.H., Liu, Y.Z., 2012. (Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains. Eur. J. Pharmacol. 674, 280-286.
31. Li, L., Holscher, C., 2007. Common pathological processes in Alzheimer's disease and type 2 diabetes: a review. Brain Res. Rev. 56, 384-402. (Pubitemid 350166529)
32. Mandelkow, E., Song, Y.-H., Schweers, O., Marx, A., Mandelkow, E.-M., 1995. On the struc-ture of microtubules, tau, and paired helical filaments. Neurobiol. Aging 16, 347-354.
33. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., Beyreuther, K., 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 82, 4245-4249. (Pubitemid 15053619)
34. McClean, P.L., Parthsarathy, V., Faivre, E., Holscher, C., 2011. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 6587-6594.
35. Oddo, S., Billings, L., Kesslak, J.P., Cribbs, D.H., Laferla, F.M., 2004. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332. (Pubitemid 39061125)
36. Park, O.K., Choi, J.H., Park, J.H., Kim, I.H., Yan, B.C., Ahn, J.H., Kwon, S.H., Lee, J.C., Kim, Y.S., Kim, M., Kang, I.J., Kim, J.D., Lee, Y.L., Won, M.H., 2012. Comparison of neuroprotective effects of five major lipophilic diterpenoids from Danshen extract against experimentally induced transient cerebral ischemic damage. Fitoterapia 83, 1666-1674.
37. Pathan, A.R., Viswanad, B., Sonkusare, S.K., Ramarao, P., 2006. Chronic administration of Pioglitazone attenuates intracerebroventricular streptozotocin inducedmemory impairment in rats. Life Sci. 79, 2209-2216. (Pubitemid 44646475)
38. Perry, T., Greig, N.H., 2002. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J. Alzheimers Dis. 4, 487-496. (Pubitemid 36142838)
39. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M., Greig, N.H., 2003. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72, 603-612. (Pubitemid 36578646)
40. Prakash, A.K., Kumar, A., 2009. Effect of chronic treatment of carvedilol on oxidative stress in an intracerebroventricular streptozotocin induced model of dementia in rats. J. Pharm. Pharmacol. 61, 1665-1672.
41. Reagan-Shaw, S., Nihal, M., Ahmad, N., 2007. Dose translation from animal to human studies revisited. FASEB J. 22, 659-661.
42. Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., Mobius, H.J., 2003. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333-1341. (Pubitemid 36384100)
43. Salkovic-Petrisic, M., Osmanovic, J., Grunblatt, E., Riederer, P., Hoyer, S., 2009. Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J. Alzheimers Dis. 18, 729-750.
44. Sehgal, N., Gupta, A., Valli, R.K., Joshi, S.D., Mills, J.T., Hamel, E., Khanna, P., Jain, S.C., Thakur, S.S., Ravindranath, V., 2012. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl. Acad. Sci. U. S. A. 109, 3510-3515.
45. Sharma, B., Singh, N., Singh, M., 2008. Modulation of celecoxib- and streptozotocininduced experimental dementia of Alzheimer's disease by Pitavastatin and Donepezil. J. Psychopharmacol. 22, 162-171. (Pubitemid 351322854)
46. Sharma, M., Gupta, Y.K., 2001. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci. 68, 1021-1029. (Pubitemid 32168054)
47. Shingo, A.S., Kanabayashi, T., Murase, T., Kito, S., 2012. Cognitive decline in STZ-3V rats is largely due to dysfunctional insulin signalling through the dentate gyrus. Behav. Brain Res. 229, 378-383.
48. Tariot, P.N., Farlow, M.R., Grossberg, G.T., Graham, S.M., McDonald, S., Gergel, I., 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J. Am. Med. Assoc. 291, 317-324. (Pubitemid 38101604)
49. Tariot, P.N., Federoff, H.J., 2003. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis. Assoc. Disord. 17, S105eS113.
50. Tiwari, V., Kuhad, A., Bishnoi, M., Chopra, K., 2009. Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol. Biochem. Behav. 93, 183-189.
51. Tota, S., Kamat, P.K., Shukla, R., Nath, C., 2011. Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav. Brain Res. 221, 207-215.
52. Wang, Y.J., Thomas, P., Zhong, J.H., Bi, F.F., Kosaraju, S., Pollard, A., Fenech, M., Zhou, X.F., 2009. Consumption of grape seed extract prevents amyloid-b deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox. Res. 15, 3-14.
53. Wyss-Coray, T., 2006. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015. (Pubitemid 44353380)
54. Yamazaki, K., Yasuda, N., Inoue, T., Nagakura, T., Kira, K., Shinoda, M., Saeki, T., Tanaka, I.Y., 2006. 7-but-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6- piperazin-1-yl- 7,9- dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity. J. Pharmacol. Exp. Ther. 319, 1253-1257.